Zoledronic acid/ Neridronic acid – USA

Zoledronic acid/ Neridronic acid – USA


PGR decision: May 05, 2020

AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
Status
PGR2019-00003
10/16/2018
05/07/2019
Grunenthal GmbH
9,867,839
Antecip Bioventures II LLC
Some Challenged Claims Unpatentable

US 9,867,839 (ANTECIP BIOVENTURES II LLC; Exp: Mar. 27, 2035)

1. A method of treating pain associated with a joint comprising: administering neridronic acid in an acid form or a salt form to a patient who has suffered for at least 3 months with 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS).
15. A method of treating pain associated with a joint comprising: orally administering zoledronic acid in an acid form or a salt form to a patient having 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS, wherein a total of about 400 mg to about 600 mg of zoledronic acid is administered in 2 or 3 individual doses within a period of about a month.
ORDER:
Claims 1–14 of the ’839 patent are unpatentable; and
Claims 15–30 of the ’839 patent are not shown to be unpatentable.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved